Log in
NASDAQ:CTXR

Citius Pharmaceuticals Stock Forecast, Price & News

$1.14
+0.04 (+3.64 %)
(As of 10/23/2020 07:59 PM ET)
Add
Compare
Today's Range
$1.10
Now: $1.14
$1.14
50-Day Range
$0.83
MA: $1.02
$1.20
52-Week Range
$0.40
Now: $1.14
$1.97
Volume351,800 shs
Average Volume1.65 million shs
Market Capitalization$63.24 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids. It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
Read More
Citius Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTXR
CUSIPN/A
Phone908-967-6677
Employees7

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.84 per share

Profitability

Net Income$-15,560,000.00

Miscellaneous

Market Cap$63.24 million
Next Earnings DateN/A
OptionableNot Optionable
$1.14
+0.04 (+3.64 %)
(As of 10/23/2020 07:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CTXR News and Ratings via Email

Sign-up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Citius Pharmaceuticals (NASDAQ:CTXR) Frequently Asked Questions

How has Citius Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Citius Pharmaceuticals' stock was trading at $0.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CTXR stock has increased by 90.0% and is now trading at $1.14.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Citius Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Citius Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Citius Pharmaceuticals
.

How were Citius Pharmaceuticals' earnings last quarter?

Citius Pharmaceuticals Inc (NASDAQ:CTXR) posted its earnings results on Thursday, May, 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.03.
View Citius Pharmaceuticals' earnings history
.

When did Citius Pharmaceuticals' stock split? How did Citius Pharmaceuticals' stock split work?

Citius Pharmaceuticals shares reverse split before market open on Friday, June 9th 2017. The 1-15 reverse split was announced on Thursday, June 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 8th 2017. An investor that had 100 shares of Citius Pharmaceuticals stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for CTXR?

2 brokers have issued 1-year price objectives for Citius Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Citius Pharmaceuticals' stock price to reach $4.00 in the next year. This suggests a possible upside of 250.9% from the stock's current price.
View analysts' price targets for Citius Pharmaceuticals
.

Are investors shorting Citius Pharmaceuticals?

Citius Pharmaceuticals saw a increase in short interest in September. As of September 30th, there was short interest totaling 809,100 shares, an increase of 15.4% from the September 15th total of 701,200 shares. Based on an average daily volume of 1,320,000 shares, the short-interest ratio is presently 0.6 days.
View Citius Pharmaceuticals' Short Interest
.

Who are some of Citius Pharmaceuticals' key competitors?

What other stocks do shareholders of Citius Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Citius Pharmaceuticals investors own include BioNano Genomics (BNGO), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Novan (NOVN), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL), KushCo (KSHB) and Gran Tierra Energy (GTE).

Who are Citius Pharmaceuticals' key executives?

Citius Pharmaceuticals' management team includes the following people:
  • Mr. Leonard L. Mazur, Exec. Chairman & Sec. (Age 74)
  • Mr. Myron Z. Holubiak, Pres, CEO & Director (Age 72)
  • Mr. Jaime Bartushak, CFO, Chief Accounting Officer & Principal Financial Officer (Age 51)
  • Mr. Gary F. Talarico, Exec. VP of Operations (Age 64)
  • Mr. Andrew Scott, VP of Corp. Devel.

What is Citius Pharmaceuticals' stock symbol?

Citius Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTXR."

How do I buy shares of Citius Pharmaceuticals?

Shares of CTXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Citius Pharmaceuticals' stock price today?

One share of CTXR stock can currently be purchased for approximately $1.14.

How big of a company is Citius Pharmaceuticals?

Citius Pharmaceuticals has a market capitalization of $63.24 million. Citius Pharmaceuticals employs 7 workers across the globe.

What is Citius Pharmaceuticals' official website?

The official website for Citius Pharmaceuticals is www.citiuspharma.com.

How can I contact Citius Pharmaceuticals?

Citius Pharmaceuticals' mailing address is 11 Commerce Drive First Floor, Cranford NJ, 07016. The company can be reached via phone at 908-967-6677.

This page was last updated on 10/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.